REFERENCES
- Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al.
The standardization of terminology in lower urinary tract function:
Report from the standardization sub-committee of the International
Continence Society. Urology. 2003;61(1):37–49.
- Turner WH, Brading AF. Smooth muscle of the bladder in the normal and
the diseased state: Pathophysiology, diagnosis, and treatment.
Pharmacol Ther. 1997;75(2):77–110.
- Bates CP, Whiteside CG, Turner‐Warwick R. synchronous
cine/pressure/flow/cystourethrography with special reference to stress
and urge incontinence. Br J Urol. 1970;42(6):714-23.
- Benner JS, Nichol MB, Rovner ES, Jumadilova Z, Alvir J, Hussein M, et
al. Patient-reported reasons for discontinuing overactive bladder
medication. BJU Int. 2010;105(9):1276–82.
- Homma Y, Gotoh M, Kawauchi A, et al. Clinical guidelines for male
lower urinary tract symptoms and benign prostatic
hyperplasia. Int J Urol . 2017;24(10):716-729.
- Yamaguchi O. Beta3-adrenoceptors in human detrusor
muscle. Urology . 2002;59(5 Suppl 1):25-29.
- Ichihara K, Masumori N, Fukuta F, Tsukamoto T, Iwasawa A, Tanaka Y. A
randomized controlled study of the efficacy of tamsulosin monotherapy
and its combination with mirabegron for overactive bladder induced by
benign prostatic obstruction. J Urol. 2015;193(3):921–6.
- Kakizaki H, Lee KS, Yamamoto O, Jong JJ, Katou D, Sumarsono B, et al.
Mirabegron Add-on Therapy to Tamsulosin for the Treatment of
Overactive Bladder in Men with Lower Urinary Tract Symptoms: A
Randomized, Placebo-controlled Study (MATCH). Eur Urol Focus.
2019;1–9.
- Kaplan SA, Herschorn S, McVary KT, et al. Efficacy and Safety of
Mirabegron versus Placebo Add-On Therapy in Men with Overactive
Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic
Hyperplasia: A Randomized, Phase 4 Study (PLUS). J Urol . 2020;
203(6):1163-1171.
- Su Shunye, Lin J, Liang L, Liu L, Chen Z, Gao Y. The efficacy and
safety of mirabegron on overactive bladder induced by benign prostatic
hyperplasia in men receiving tamsulosin therapy: A systematic review
and meta-analysis. Medicine (Baltimore) . 2020; 99(4):e18802.
- Matsuo T, Miyata Y, Kakoki K, Yuzuriha M, Asai A, Ohba K, et al. The
efficacy of mirabegron additional therapy for lower urinary tract
symptoms after treatment with α1-adrenergic receptor blocker
monotherapy: Prospective analysis of elderly men. BMC Urol.
2016;16(1):1–7.
- Wada N, Iuchi H, Kita M, Hashizume K, Matsumoto S, Kakizaki H.
Urodynamic Efficacy and Safety of Mirabegron Add-on Treatment with
Tamsulosin for Japanese Male Patients with Overactive Bladder.LUTS: Lower Urinary Tract Symptoms 2016;8(3):171–6.
- Lee M. Tamsulosin for the treatment of benign prostatic
hypertrophy. Ann Pharmacother . 2000; (2):188-199.
- Lee SW, Doo SW, Yang WJ, Song YS. Importance of relieving the most
bothersome symptom for improving quality of life in male patients with
lower urinary tract symptoms. Urology . 2012; 80(3):684-687.
- Kuo HC, Lee KS, Na Y, et al. Results of a randomized, double-blind,
parallel-group, placebo- and active-controlled, multicenter study of
mirabegron, a β3-adrenoceptor agonist, in patients with overactive
bladder in Asia. Neurourol Urodyn 2015; 34(7):685-692.
- Oelke M, Speakman MJ, Desgrandchamps F, Mamoulakis C. Acute Urinary
Retention Rates in the General Male Population and in Adult Men With
Lower Urinary Tract Symptoms Participating in Pharmacotherapy Trials:
A Literature Review. Urol2015; 86(4):654-665.
- Drake MJ, MacDiarmid S, Al-Shukri S, et al. Adding Mirabegron to
Solifenacin to Treat Overactive Bladder Has Little Impact on Postvoid
Residual Volume or Urinary Retention Risk. Urol2017; 104:1-4.
- Sudrania MK, Dangi AD, Kumar S, Kumar B, Kekre NS. Urodynamic outcomes
of tamsulosin in the treatment of primary bladder neck obstruction in
men. Ind J Urol 2018; 34:34-8.
- Kaplan SA, Roehrborn CG, Rovner ES, et al. Tolterodine and tamsulosin
for treatment of men with lower urinary tract symptoms and overactive
bladder: a randomized controlled trial. JAMA2006; 296:2319-2328.
- Kaplan SA, McCammon K, Fincher R, et al. Safety and tolerability of
solifenacin add-on therapy to alpha-blocker treated men with residual
urgency and frequency. J.Urol 2009; 182: 2825-2830.
- MacDiarmid SA, Peters KM, Chen A, et al. Efficacy and safety of
extended-release oxybutynin in combination with tamsulosin for
treatment of lower urinary tract symptoms in men: randomized,
double-blind, placebo-controlled study. Mayo Clin Proc. 2008; 83:
1002-1010.
- Yamaguchi O, Kakizaki H, Homma Y, et al. Solifenacin as add-on therapy
for overactive bladder symptoms in men treated for lower urinary tract
symptoms ASSIST, randomized controlled study. Urol2011; 78:126-133.
- Alexandre EC, Kiguti LR, Calmasini FB, Silva FH, Silva KP, Ferreira R
and et al.Mirabegron relaxes urethral smooth muscle by a dual
mechanism involving β3 -adrenoceptor activation and α1 -adrenoceptor
blockade. Br J Pharmacol 2016;173:415–428.
- Singh I, TK Aravind, Gupta S. Efficacy andsafety of tadalafil vs
tamsulosin in lower urinary tractsymptoms (LUTS) as a result of
(BPH)—open label randomised controlled study. Int J ClinPract.
2020;00:e13530.
- Singh DV, Mete UK, Mandal AK, Singh SK. A comparative randomized
prospectivestudy to evaluate efficacy and safety of combination of
tamsulosin and tadalafil vs tamsulosin or tadalafil alone in patients
with lower urinary tract symptoms due to BPH. J Sex Med.
2014;11(1):187-96.
- Takahashi S, Kato D, Tabuchi H, Uno S. Safety and effectiveness of
mirabegron in male patients with overactive bladder with or without
benign prostatic hyperplasia: A Japanese post‐marketing study. LUTS
2020;1–9.DOI: 10.1111/luts.12335
- Shin DG, Kim HW, YoonSJ, et al. Mirabegron as a treatment for
overactivebladder symptoms in men (MIRACLE study):Efficacy and safety
results from a multicenter,randomized, double-blind,
placebo-controlled,parallel comparison phase IV study. NeuroUrol
Urodynamics. 2018;1–10.
- Singh I, Agarwal V, Garg G. ’Tamsulosin and Darifenacin’ Versus
’TamsulosinMonotherapy’ for ’BPH with Accompanying Overactive
Bladder’. J Clin Diag Res2015;9(6):PC08-11.
LEGENDS FOR FIG & TABLES :
Fig 1: Figure depicting the flow of the current study protocol
Table 1 (a-b): Table 1a depicting the baseline and demographic features
of the patient parameters and Table 1b depicting the post treatment
parameters of the same in the two groups.
Table 2: Depicting a summary of mirabegron comparative studies on BPH
induced OABS. Table 3 (a-c): Table 3 depicting a comparison previous
similar study designs with the present studywith respect to OABSS total
score improvement (Table3a); IPSS-ss score improvement (Table 3b) and
change in the PVR (Table 3c) in both the patient groups.